Georg Lenz
Georg Lenz is an expert in Hematology at University Hospital Münster (Germany). As of October 2026, ScienceLeadR ranks Georg Lenz in the top 1% of experts worldwide for Lymphoma and Lymphoproliferative Disorders. Georg Lenz has authored 488 publications, the most recent in 2026, and is an investigator in 18 clinical trials, 1 of them ongoing. SLR score: 2,067 (community average: 125). How the SLR is computed.
LeadR Profile
Hematology
Subspecialties: Oncology - Immunology - Transplantation
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2003 - 2026
Number : 488
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Outcomes of front-line tagraxofusp in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) in a real-world scenario. PMID 42844632 — cells, hematology, blood, microscopy, electron, scanning transmission, neoplasms, stem cells, dendritic cells, cell transplantation, stem cell transplantation, transplantation | J Hematol Oncol Top journal | 2026 | 0 |
| Extranodal Organ Involvement in Chronic Lymphocytic Leukemia: Clinical Features and Outcomes With Bruton Tyrosine Kinase and BCL-2 Inhibitors. PMID 42830438 — genes, bcl-2, neoplasms, leukemia, lymphocytic, chronic, b-cell, leukemia, leukemia, lymphoid, lymph, protein-tyrosine kinases, risk factors, diagnosis, agammaglobulinaemia tyrosine kinase, tyrosine, therapeutics | Cancer Med | 2026 | 0 |
| Measurable residual disease-negative remission of BRAF-V600Emutated acute myeloid leukemia with dabrafenib and trametinib. PMID 42817851 — hematology, leukemia, leukemia, myeloid, acute, leukemia, myeloid | Haematologica | 2026 | 0 |
| LymphGen-Sig: Integrating Genetic and Transcriptional States to Predict Therapeutic Response in Diffuse Large B-Cell Lymphoma. PMID 42715516 — cells, genes, lymphoma, b-cell, lymphoma, lymphoma, large b-cell, diffuse, classification, therapeutics, mutation, b-lymphocytes, gene expression | J Clin Oncol Top journal | 2026 | 0 |
| Low lymphoma macrophage infiltration predicts poor outcomes for R-CHOP- but not Pola-R-CHP-treated patients with DLBCL. PMID 42699559 — lymphoma, macrophages, lymphoma, large b-cell, diffuse, therapeutics | Blood Neoplasia | 2026 | 0 |
Clinical Studies 18
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
Ongoing trial started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Tafasitamab Lenalidomide R CHOP Versus R CHOP in Newly Diagnosed High intermediate and High Risk DLBCL Patients NCT04824092 — cells, safety, saline solution, prednisone, lymphoma, b-cell, lymphoma, lymphoma, large b-cell, diffuse, cyclophosphamide, doxorubicin, solutions, rituximab, vincristine, antibodies, monoclonal, lenalidomide, b-lymphocytes | Phase 3 | Active not recruiting | 2021 |
LeadR Networks
Main global connection map